IOP Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma or Ocular Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

136 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-08-31

Study Completion Date

2007-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the safety and IOP-lowering efficacy of a fixed combination of Travoprost/Brinzolamide Ophthalmuc Suspension dosed BID and QD, to TRAVATAN dosed QD and a Vehicle dosed BID in patients with open-angle glaucoma or ocular hypertension.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT02140060

Glaucoma Ocular Hypertension

COMPLETED PHASE2

A Phase III Study of Travoprost/Timolol Combination in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT00672997

Open-Angle Glaucoma Ocular Hypertension

COMPLETED PHASE3

Safety and Intraocular Pressure (IOP) Lowering Efficacy of Low Dose Travoprost

NCT00637130

Open-angle Glaucoma Ocular Hypertension

COMPLETED PHASE2

Travoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPT

NCT00767494

Glaucoma Ocular Hypertension

TERMINATED PHASE3

Safety and Efficacy of Travoprost/Timolol BAC-free

NCT00760539

Open-Angle Glaucoma Ocular Hypertension

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Open-angle Glaucoma Ocular Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Travoprost/brinzolamide

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients 18 years of age or older of either sex and any race with diagnosed open-angle glaucoma or confirmed ocular hypertension

Exclusion Criteria

* Age (Under 18)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Theresa Landry

Role: STUDY_DIRECTOR

Alcon Research

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Artesia

Artesia, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

C-07-07

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

NCT00293761 COMPLETED PHASE3

Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

NCT00966940 COMPLETED PHASE4

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

NCT00051142 COMPLETED PHASE3

Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension

NCT00372827 COMPLETED PHASE4

Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension

NCT00763061 COMPLETED PHASE4

Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)

NCT00758342 TERMINATED PHASE4

Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension

NCT00061503 COMPLETED PHASE4

Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension

NCT06152861 RECRUITING PHASE2

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma

NCT00051181 COMPLETED PHASE3

1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPT

NCT00767481 TERMINATED PHASE3

Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure

NCT02003391 COMPLETED PHASE4

A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension

NCT00471380 COMPLETED PHASE4

Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%

NCT01452009 WITHDRAWN PHASE3

Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT00670033 COMPLETED PHASE2

Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%

NCT01297920 COMPLETED PHASE3

Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OH

NCT01721707 WITHDRAWN PHASE3

Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma

NCT01995136 COMPLETED PHASE4

Efficacy Study of Travoprost APS Versus TRAVATAN

NCT00848536 COMPLETED PHASE3

Travoprost 0.004%/Timolol 0.5% Versus Latanoprost 0.005%/Timolol in Chinese Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT00872651 COMPLETED PHASE3

Travoprost 3-Month Safety and Efficacy Study

NCT01453855 COMPLETED PHASE3

Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension

NCT01309204 COMPLETED PHASE3

Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%

NCT01297517 COMPLETED PHASE3

Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension

NCT01310777 COMPLETED PHASE3

Travoprost Five Day Posology Study

NCT01114893 COMPLETED PHASE2